VIRalliance develops and markets high added value services and products to help optimise drug discovery and patient treatment in the fields of infectious diseases and oncology. VIRalliance has a development portfolio of innovative predictive tests to aid the optimal treatment. PHENOSCRIPT™ is the first of these tests to be made available to the public.
PHENOSCRIPT™ is a novel and rapid HIV phenotypic test used to measure resistance to antiretroviral drugs used in HIV therapy. Treatment failure can occur in HIV/AIDS patients when the virus develops resistance to drug therapy. Physicians use the test to select the most effective HIV drug therapy for the individual patient. With more clinically relevant cut-offs than any other commercially available HIV drug susceptibility test, the PHENOSCRIPT™ Report provides clear and concise recommendations to facilitate the choice of optimal treatments. The superior reliability and accuracy of PHENOSCRIPT™ have been validated through extensive study by independent investigators.
News